Begin main content


Last Updated: November 5, 2019
Result type: Reports
Project Number: SR0626-000
Product Line: Common Drug Review

Generic Name: glucagon

Brand Name: Baqsimi

Manufacturer: Eli Lilly Canada Inc.

Indications: Severe hypoglycemic reactions

Manufacturer Requested Reimbursement Criteria1: For the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates.

Submission Type: New

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedJune 25, 2019
Patient group input closedAugust 15, 2019

- Patient input submission received from Diabetes Canada and Type 1 Together/Ensemble

Patient input summary sent for review to patient input groupsSeptember 12, 2019
Patient group comments on input summary closedSeptember 19, 2019

- Patient input summary feedback received

Submission receivedJuly 24, 2019
Submission accepted for reviewAugust 08, 2019
Review initiatedAugust 09, 2019
Draft CADTH review report(s) sent to sponsorOctober 24, 2019
Comments from sponsor on draft CADTH review report(s) receivedNovember 04, 2019
CADTH review team's comments on draft CADTH review report(s) sent to sponsorNovember 29, 2019
Canadian Drug Expert Committee (CDEC) meetingDecember 11, 2019
CDEC recommendation sent to sponsor and drug plansDecember 23, 2019
January 02, 2020